Bank of America Securities Raises Hansoh Pharmaceutical (03692.HK) Target Price to HK$29, Reiterates 'Buy' Rating

According to the Zhicheng Caijing APP, a research report issued by Bank of America Securities stated that the sales of almonertinib tablets, produced by Hansoh Pharma (03692), surged 76.9% in the first two months of this year, driving the company's strong sales performance. Consequently, the revenue forecasts for 2025, 2026, and 2027 have been raised by 1.9%, 2.5%, and 2.7% respectively, with the target price increasing from HK$24.8 to HK$29. Due to its robust R&D capabilities and expanded indications for existing key products, the "Buy" rating has been reiterated.